Letter to the Editor—Journal of Cardiovascular Translational Research

This issue’s focus on women and cardiovascular medicine is timely and critically important. Recently published studies have underscored, yet again, that cardiovascular disease research must more effectively and aggressively target women if it is to produce results that lead to improved prevention and early detection, accurate diagnosis, and proper treatment for women. Specifically, one study found that women have been underrepresented in NIH-supported cardiovascular randomized controlled trials conducted in the past 10 years, despite a 1993 federal law requiring clinical trials to include a significant proportion of women [1]. Possible reasons for this failure are varied, ranging from a lack of information about the availability of clinical trials by women patients and their healthcare providers to study designs that exclude women heart patients due to their medical conditions, medications, or history. Pragmatic concerns by women patients about how participation in a clinical trial will affect their health insurance coverage and the logistical difficulties of transportation and childcare also have an adverse effect on participation rates [2]. The impact of failing to overcome these barriers and significantly increasing the number of women in clinical trials has contributed to a substantial deficit of gender-based knowledge about everything from the “typical ” heart attack symptoms in women to the risks and benefits of commonly used diagnostic tests and therapies [3]. Exacerbating this problem are the serious lapses in the U.S

Comparison of breast and bowel cancer screening uptake patterns in a common cohort of South Asian women in England

Background: Inequalities in uptake of cancer screening by ethnic minority populations are well documented in a number of international studies. However, most studies to date have explored screening uptake for a single cancer only. This paper compares breast and bowel cancer screening uptake for a cohort of South Asian women invited to undertake both, and similarly investigates these women's breast cancer screening behaviour over a period of fifteen years. Methods: Screening data for rounds 1, 2 and 5 (1989-2004) of the NHS breast cancer screening programme and for round 1 of the NHS bowel screening pilot (2000-2002) were obtained for women aged 50-69 resident in the English bowel screening pilot site, Coventry and Warwickshire, who had been invited to undertake breast and bowel cancer screening in the period 2000-2002. Breast and bowel cancer screening uptake levels were calculated and compared using the chi-squared test. Results: 72,566 women were invited to breast and bowel cancer screening after exclusions. Of these, 3,539 were South Asian and 69,027 non-Asian; 18,730 had been invited to mammography over the previous fifteen years (rounds 1 to 5). South Asian women were significantly less likely to undertake both breast and bowel cancer screening; 29.9% (n = 1,057) compared to 59.4% (n = 40,969) for non-Asians (p < 0.001). Women in both groups who consistently chose to undertake breast cancer screening in rounds 1, 2 and 5 were more likely to complete round 1 bowel cancer screening. However, the likelihood of completion of bowel cancer screening was still significantly lower for South Asians; 49.5% vs. 82.3% for non-Asians, p < 0.001. South Asian women who undertook breast cancer screening in only one round were no more likely to complete bowel cancer screening than those who decided against breast cancer screening in all three rounds. In contrast, similar women in the non-Asian population had an increased likelihood of completing the new bowel cancer screening test. The likelihood of continued uptake of mammography after undertaking screening in round 1 differed between South Asian religio-linguistic groups. Noticeably, women in the Muslim population were less likely to continue to participate in mammography than those in other South Asian groups. Conclusions: Culturally appropriate targeted interventions are required to reduce observed disparities in cancer screening uptakes

Cardiovascular magnetic resonance in systemic hypertension

Systemic hypertension is a highly prevalent potentially modifiable cardiovascular risk factor. Imaging plays an important role in the diagnosis of underlying causes for hypertension, in assessing cardiovascular complications of hypertension, and in understanding the pathophysiology of the disease process. Cardiovascular magnetic resonance (CMR) provides accurate and reproducible measures of ventricular volumes, mass, function and haemodynamics as well as uniquely allowing tissue characterization of diffuse and focal fibrosis. In addition, CMR is well suited for exclusion of common secondary causes for hypertension. We review the current and emerging clinical and research applications of CMR in hypertension